by Truveta Research | May 14, 2025 | Research, Research Insights
Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD, PhD ⊕Truveta, Inc, Bellevue, WA Side effects were the most common...
by Truveta staff | Mar 7, 2025 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in December 2024 were similar to September 2024 (+1.89%). Anti-diabetic medication (ADM) prescribing rates in December 2024 were similar to those in September 2024 (-0.88%). Among ADMs,...
by Truveta Research | Dec 16, 2024 | Research, Research Insights
In partnership with Reuters, Truveta Research explored the percentage of patients who received a first-time diagnosis of type 2 diabetes, cardiovascular disease, or sleep apnea within 15 days of their first-time GLP-1 prescriptions. Truveta Research found that for...
by Truveta staff | Nov 7, 2024 | Data
GLP-1 medications are revolutionizing the way we treat type 2 diabetes and obesity. First discovered forty years ago, GLP-1 receptor agonists were initially approved for type 2 diabetes in 2005, with the first weight-loss-specific approval following in 2014. Flash...
by Truveta Research | Jul 23, 2024 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2024 increased slightly relative to March 2024 (+8.43%). Month-over-month anti-diabetic medication (ADM) prescribing increased in April and May 2024 then decreased slightly in June...
